...
首页> 外文期刊>Annals of hematology >Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study.
【24h】

Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study.

机译:中国骨髓增生异常综合征患者的细胞遗传学特征和预后分析:一项多中心研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

It has been suggested that Asian and Western myelodysplastic syndrome (MDS) patients have different cytogenetic and prognostic features. In this study, we retrospectively analyzed clinical and cytogenetic data from 435 Chinese adult primary MDS patients. In addition, we evaluated the prognostic value of the World Health Organization classification as well as six prognostic scoring systems in these patients. The median follow-up time was 25.1 months (5.5-53.2). Of the 435 patients, 186 (42.8%) had died and 40 (9.2%) had progressed to acute myeloid leukemia. Multivariate analysis identified older age, higher percent of marrow blasts, and poor-risk IPSS cytogenetics as characteristics associated with worse survival and higher risk of leukemia transformation. Low platelets, hemoglobin, and mean corpuscular volume were independent factors associated only with worse survival. Among the 424 patients in whom the results of cytogenetic analyses were available, 164 (38.7%) showed karyotypic abnormalities. Incidence of trisomy 8 was common but sole del(5q) was rare in Chinese MDS patients. For predicting survival, most scoring systems were meaningful for stratifying patients into different subgroups, with the exception of the WPSS scoring system. For predicting leukemia evolution, the Spanish scoring system was most effective. Patients with RAEB-2 showed different prognoses from those with RAEB-1. However, there was no significant difference in prognoses between patients with refractory cytopenia with multilineage dysplasia (RCMD) from RA or RARS. In summary, this analysis indicated the presence of a different cytogenetic pattern as well as prognostic features in Chinese MDS patients.
机译:已经提出,亚洲和西方的骨髓增生异常综合症(MDS)患者具有不同的细胞遗传学和预后特征。在这项研究中,我们回顾性分析了435名中国成人原发性MDS患者的临床和细胞遗传学数据。此外,我们评估了世界卫生组织分类的预后价值以及这些患者的六个预后评分系统。中位随访时间为25.1个月(5.5-53.2)。在435名患者中,有186名(42.8%)死亡,而40名(9.2%)已发展为急性髓细胞性白血病。多变量分析表明年龄较大,骨髓胚细胞百分比较高以及IPSS遗传风险低是与生存期较差和白血病转化风险较高相关的特征。低血小板,血红蛋白和平均红细胞体积是仅与较差生存率相关的独立因素。在获得细胞遗传学分析结果的424例患者中,有164例(38.7%)显示出核型异常。在中国MDS患者中,三体性8的发病率很普遍,但唯一的del(5q)很少。为了预测生存,除WPSS评分系统外,大多数评分系统对于将患者分为不同的亚组都是有意义的。对于预测白血病的演变,西班牙的评分系统最为有效。 RAEB-2患者的预后与RAEB-1患者不同。但是,来自RA或RARS的难治性血细胞减少症伴多谱系发育不良(RCMD)患者的预后没有显着差异。总而言之,这项分析表明中国MDS患者存在不同的细胞遗传学模式以及预后特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号